Mineralization of the connective tissue: A complex molecular process leading to age-related loss of function

Rejuvenation Research

Volumn 17, Issue 2, 2014, Pages 116-133

  Shindyapina, Anastasia V ^a,b,c,d   Mkrtchyan, Garik V ^a,b,d   Gneteeva, Tatiana ^d,e   Buiucli, Sveatoslav ^c,d   Tancowny, B ^f,g   Kulka, M ^f,g   Aliper, Alexander ^b,c,d   Zhavoronkov, Alexander ^b,c,d,h  

^a MOSCOW STATE UNIVERSITY   (Russian Federation)

^b Center for Pediatric Hematology Oncology and Immunology   (Russian Federation)

^c MOSCOW INSTITUTE OF PHYSICS AND TECHNOLOGY   (Russian Federation)

^d First Open Institute for Regenerative Medicine for Young Scientists   (Russian Federation)

^e I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^f UNIVERSITY OF ALBERTA   (Canada)

^g NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^h Biogerontology Research Foundation   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BONE MORPHOGENETIC PROTEIN; COLLAGEN; FIBROBLAST GROWTH FACTOR; FRESOLIMUMAB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; METELIMUMAB; PIOGLITAZONE; PROCOLLAGEN LYSINE 2 OXOGLUTARATE 5 DIOXYGENASE; PROTEIN LYSINE 6 OXIDASE; MINERAL;

AGE; AGING; ARTICLE; ATHEROSCLEROSIS; BIOINFORMATICS; BLOOD VESSEL CALCIFICATION; BONE DISEASE; BONE MINERALIZATION; CHRONIC KIDNEY DISEASE; CONNECTIVE TISSUE; CRANIOFACIAL SYNOSTOSIS; CROSS LINKING; HORMONE SUBSTITUTION; HUMAN; KIDNEY POLYCYSTIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL COHERENCE TOMOGRAPHY; OSSIFICATION; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PSEUDOXANTHOMA ELASTICUM; RIGIDITY; SOFT TISSUE CALCIFICATION; TISSUE DEGENERATION; TISSUE MINERALIZATION; ANIMAL; CALCINOSIS; GENETIC PREDISPOSITION; GENETICS; METABOLISM; PATHOLOGY;

AGING; ANIMALS; CALCINOSIS; CONNECTIVE TISSUE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MINERALS;

EID: 84898977454     PISSN: 15491684     EISSN: 15578577     Source Type: Journal    
DOI: 10.1089/rej.2013.1475     Document Type: Article

References (121)

1. Mello MA, Tuan RS. High density micromass cultures of embryonic limb bud mesenchymal cells: An in vitro model of endochondral skeletal development. In Vitro Cell Dev Biol Anim 1999;35:262-269. (Pubitemid 29252105)
2. Canfield AE, Doherty MJ, Wood AC, Farrington C, Ashton B, Begum N, et al. Role of pericytes in vascular calcification: A review. Z Kardiol 2000;89(Suppl 2):20-27.
3. Brakus SM, Govorko DK, Vukojevic K, Jakus IA, Carev D, Petricevic J, et al. Apoptotic and anti-apoptotic factors in early human mandible development. Eur J Oral Sci 2010; 118:537-546.
4. Shibata S, Suzuki S, Tengan T, Ishii M, Kuroda T. A histological study of the developing condylar cartilage of the fetal mouse mandible using coronal sections. Arch Oral Biol 1996;41:47-54.
5. Wu M, Rementer C, Giachelli CM. Vascular calcification: An update on mechanisms and callenges in treatment. Calcif Tissue Int 2013; published online March 1, 2013; doi 10.1007/s00223-013-9712-z.
6. Doherty TM, Detrano RC. Coronary arterial calcification as an active process: A new perspective on an old problem. Calcif Tissue Int 1994;54:224-230. (Pubitemid 24076579)
7. Resnick D. Diagnosis of Bone and Joint Disorders, 4th ed. Saunders, Philadelphia, 2002.
8. Takasu J, Takanashi K, Naito S, Onishi M, Miyazaki A, Aoyagi Y, et al. Evaluation of morphological changes of the atherosclerotic aorta by enhanced computed tomography. Atherosclerosis 1992;97:107-121.
9. Lee JS, Morrisett JD, Tung CH. Detection of hydroxyapatite in calcified cardiovascular tissues. Atherosclerosis 2012;224: 340-347.
10. Sell DR, Biemel KM, Reihl O, Lederer MO, Strauch CM, Monnier VM. Glucosepane is a major protein cross-link of the senescent human extracellular matrix. Relationship with diabetes. J Biol Chem 2005;280:12310-12315.
11. Sims TJ, Rasmussen LM, Oxlund H, Bailey AJ. The role of glycation cross-links in diabetic vascular stiffening. Diabetologia 1996;39:946-951. (Pubitemid 26249114)
12. Basalyga DM, Simionescu DT, Xiong W, Baxter BT, Starcher BC, Vyavahare NR. Elastin degradation and calcification in an abdominal aorta injury model: Role of matrix metalloproteinases. Circulation 2004;110:3480-3487. (Pubitemid 39602227)
13. Masuyama R, Stockmans I, Torrekens S, Van Looveren R, Maes C, Carmeliet P, et al. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J Clin Invest 2006;116:3150-3159. (Pubitemid 44878629)
14. Lane NE, Parimi N, Corr M, Yao W, Cauley JA, Nielson CM, et al. Association of serum fibroblast growth factor 23 (FGF23) and incident fractures in older men: The osteoporotic fractures in men (MrOS) study. J Bone Miner Res 2013;doi: 10.1002/jbmr.1985
15. Martin A, David V, Li H, Dai B, Feng JQ, Quarles LD. Overexpression of the DMP1 C-terminal fragment stimulates FGF23 and exacerbates the hypophosphatemic rickets phenotype in Hyp mice. Mol Endocrinol 2012;26:1883- 1895.
16. Beck-Nielsen SS, Brixen K, Gram J, Brusgaard K. Mutational analysis of PHEX, FGF23, DMP1, SLC34A3 and CLCN5 in patients with hypophosphatemic rickets. J Hum Genet 2012;57:453-458.
17. Allanson JE. Noonan syndrome. J Med Genet 1987;24:9-13. (Pubitemid 17228867)
18. Saito T, Shimizu Y, Hori M, Taguchi M, Igarashi T, Fukumoto S, et al. A patient with hypophosphatemic rickets and ossification of posterior longitudinal ligament caused by a novel homozygous mutation in ENPP1 gene. Bone 2011;49: 913-916.
19. Bergwitz C, Juppner H. FGF23 and syndromes of abnormal renal phosphate handling. Adv Exp Med Biol 2012;728:41-64.
20. Xiao L, Esliger A, Hurley MM. Nuclear fibroblast growth factor 2 (FGF2) isoforms inhibit bone marrow stromal cell mineralization through FGF23/FGFR/MAPK in vitro. J Bone Miner Res 2013;28:35-45.
21. Kobayashi K, Imanishi Y, Koshiyama H, Miyauchi A, Wakasa K, Kawata T, et al. Expression of FGF23 is correlated with serum phosphate level in isolated fibrous dysplasia. Life Sci 2006;78:2295-2301.
22. Dai B, David V, Alshayeb HM, Showkat A, Gyamlani G, Horst RL, et al. Assessment of 24,25(OH)2D levels does not support FGF23-mediated catabolism of vitamin D metabolites. Kidney Int 2012;82:1061-1070.
23. Reichrath J. Unravelling of hidden secrets: The role of vitamin D in skin aging. Dermatoendocrinol 2012;4:241-244.
24. Quarles LD. A systems biology preview of the relationships between mineral and metabolic complications in chronic kidney disease. Semin Nephrol 2013;33:130-142.
25. Bostrom KI, Jumabay M, Matveyenko A, Nicholas SB, Yao Y. Activation of vascular bone morphogenetic protein signaling in diabetes mellitus. Circ Res 2011;108:446-457.
26. Kaden JJ, Bickelhaupt S, Grobholz R, Vahl CF, Hagl S, Brueckmann M, et al. Expression of bone sialoprotein and bone morphogenetic protein-2 in calcific aortic stenosis. J Heart Valve Dis 2004;13:560-566.
27. Anderson L, Lowery JW, Frank DB, Novitskaya T, Jones M, Mortlock DP, et al. Bmp2 and Bmp4 exert opposing effects in hypoxic pulmonary hypertension. Am J Physiol Regul Integr Comp Physiol 2010;298:R833-R842.
28. MacGrogan D, Luna-Zurita L, de la Pompa JL. Notch signaling in cardiac valve development and disease. Birth Defects Res A Clin Mol Teratol 2011;91:449-459.
29. Seya K, Yu Z, Kanemaru K, Daitoku K, Akemoto Y, Shibuya H, et al. Contribution of bone morphogenetic protein- 2 to aortic valve calcification in aged rat. J Pharmacol Sci 2011;115:8-14.
30. Mahlawat P, Ilangovan U, Biswas T, Sun LZ, Hinck AP. Structure of the Alk1 extracellular domain and characterization of its bone morphogenetic protein (BMP) binding properties. Biochemistry 2012;51:6328-6341.
31. Yao Y, Zebboudj AF, Torres A, Shao E, Bostrom K. Activinlike kinase receptor 1 (ALK1) in atherosclerotic lesions and vascular mesenchymal cells. Cardiovasc Res 2007;74: 279-289. (Pubitemid 46517503)
32. Yao Y, Zebboudj AF, Shao E, Perez M, Bostrom K. Regulation of bone morphogenetic protein-4 by matrix GLA protein in vascular endothelial cells involves activin-like kinase receptor 1. J Biol Chem 2006;281:33921-33930. (Pubitemid 46036604)
33. Yao Y, Bennett BJ, Wang X, Rosenfeld ME, Giachelli C, Lusis AJ, et al. Inhibition of bone morphogenetic proteins protects against atherosclerosis and vascular calcification. Circ Res 2010;107:485-494.
34. Nitschke Y, Rutsch F. Genetics in arterial calcification: lessons learned from rare diseases. Trends Cardiovasc Med 2012;22:145-149.
35. Gliem M, Zaeytijd JD, Finger RP, Holz FG, Leroy BP, Charbel Issa P. An update on the ocular phenotype in patients with pseudoxanthoma elasticum. Front Genet 2013;4:14.
36. Lohmander LS, Englund PM, Dahl LL, Roos EM. The longterm consequence of anterior cruciate ligament and meniscus injuries: Osteoarthritis. Am J Sports Med 2007;35: 1756-1769. (Pubitemid 47476065)
37. Abraham AC, Moyer JT, Villegas DF, Odegard GM, Haut Donahue TL. Hyperelastic properties of human meniscal attachments. J Biomech 2011;44:413-418.
38. Villegas DF, Hansen TA, Liu DF, Donahue TL. A quantitative study of the microstructure and biochemistry of the medial meniscal horn attachments. Ann Biomed Eng 2008; 36:123-131. (Pubitemid 50002701)
39. Biemond JE, Hannink G, Verdonschot N, Buma P. Bone ingrowth potential of electron beam and selective laser melting produced trabecular-like implant surfaces with and without a biomimetic coating. J Mater Sci Mater Med 2013;24:745-753.
40. Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol 2009;20:1453-1464.
41. Yang J, Li X, Al-Lamki RS, Southwood M, Zhao J, Lever AM, et al. Smad-dependent and smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo. Circ Res 2010;107:252-262.
42. Shao JS, Cai J, Towler DA. Molecular mechanisms of vascular calcification: Lessons learned from the aorta. Arterioscler Thromb Vasc Biol 2006;26:1423-1430. (Pubitemid 44288965)
43. Chen D, Tian W, Li Y, Tang W, Zhang C. Osteoblastspecific transcription factor Osterix (Osx) and HIF-1alpha cooperatively regulate gene expression of vascular endothelial growth factor (VEGF). Biochem Biophys Res Commun 2012;424:176-181.
44. Yao Y, Jumabay M, Ly A, Radparvar M, Wang AH, Abdmaulen R, et al. Crossveinless 2 regulates bone morphogenetic protein 9 in human and mouse vascular endothelium. Blood 2012;119:5037-5047.
45. Jumabay M, Abdmaulen R, Urs S, Heydarkhan-Hagvall S, Chazenbalk GD, JordanMC, et al. Endothelial differentiation in multipotent cells derived from mouse and human white mature adipocytes. J Mol Cell Cardiol 2012;53:790-800.
46. Nigam V, Srivastava D. Notch1 represses osteogenic pathways in aortic valve cells. J Mol Cell Cardiol 2009;47: 828-834.
47. Garg V, Muth AN, Ransom JF, Schluterman MK, Barnes R, King IN, et al. Mutations in NOTCH1 cause aortic valve disease. Nature 2005;437:270-274. (Pubitemid 41294491)
48. Byon CH, Javed A, Dai Q, Kappes JC, Clemens TL, Darley- Usmar VM, et al. Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling. J Biol Chem 2008;283: 15319-15327.
49. Sun Y, Byon CH, Yuan K, Chen J, Mao X, Heath JM, et al. Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification. Circ Res 2012;111:543-552.
50. Kundu M, Javed A, Jeon JP, Horner A, Shum L, Eckhaus M, et al. Cbfbeta interacts with Runx2 and has a critical role in bone development. Nat Genet 2002;32:639-644. (Pubitemid 35435177)
51. Dungey M, Hull KL, Smith AC, Burton JO, Bishop NC. Inflammatory factors and exercise in chronic kidney disease. Int J Endocrinol 2013;2013:569831.
52. Hu MC, Kuro-o M, Moe OW. Renal and extrarenal actions of Klotho. Semin Nephrol 2013;33:118-129.
53. Fliser D, Seiler S, Heine GH, Ketteler M. Measurement of serum soluble Klotho levels in CKD 5D patients: useful tool or dispensable biomarker? Nephrol Dial Transplant 2012;27:1702-1703.
54. Russo D, Morrone LF, Imbriaco M, Pota A, Russo L, Scognamiglio B, et al. Coronary artery calcification and outcomes in diabetic patients with and without chronic kidney disease. Blood Purif 2013;36:17-20.
55. Negri AL. Vascular calcifications in chronic kidney disease: Are there new treatments? Curr Vasc Pharmacol 2005;3: 181-184. (Pubitemid 40601586)
56. Soltau J, Zirrgiebel U, Esser N, Schachtele C, Totzke F, Unger C, et al. Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model. Anticancer Res 2008;28:933-941. (Pubitemid 351578940)
57. Matsumoto T, Fukushima S, Kanasaki T, Hagino S. Relationship between aortic mineral elements and osteodystrophy in mice with chronic kidney disease. Biol Trace Elem Res 2012;150:278-284.
58. Dammanahalli KJ, Stevens S, Terkeltaub R. Vanin-1 pantetheinase drives smooth muscle cell activation in postarterial injury neointimal hyperplasia. PLoS One 2012; 7:e39106.
59. Jansen PA, van Diepen JA, Ritzen B, Zeeuwen PL, Cacciatore I, Cornacchia C, et al. Discovery of small molecule vanin inhibitors: New tools to study metabolism and disease. ACS Chem Biol 2013;8:530-534.
60. Di Leandro L, Maras B, Schinina ME, Dupre S, Koutris I, Martin FM, et al. Cystamine restores GSTA3 levels in Vanin-1 null mice. Free Radic Biol Med 2008;44:1088- 1096.
61. Berruyer C, Pouyet L, Millet V, Martin FM, LeGoffic A, Canonici A, et al. Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor gamma activity. J Exp Med 2006;203:2817-2827. (Pubitemid 46026160)
62. Cheng SL, Shao JS, Behrmann A, Krchma K, Towler DA. Dkk1 and Msx2-Wnt7b signaling reciprocally regulate the endothelial-mesenchymal transition in aortic endothelial cells. Arterioscler Thromb Vasc Biol 2013;33:1679-1689.
63. Shao JS, Cheng SL, Charlton-Kachigian N, Loewy AP, Towler DA. Teriparatide (human parathyroid hormone (1- 34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. J Biol Chem 2003;278:50195-50202. (Pubitemid 37548859)
64. Shao JS, Cheng SL, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, Towler DA. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest 2005, 115(5): 1210-1220. (Pubitemid 40629039)
65. Riek AE, Towler DA. The pharmacological management of osteoporosis. Missouri Med 2011;108:118-123.
66. Chen JH, Yip CY, Sone ED, Simmons CA. Identification and characterization of aortic valve mesenchymal progenitor cells with robust osteogenic calcification potential. Am J Pathol 2009;174:1109-1119.
67. Hajdu Z, Romeo SJ, Fleming PA, Markwald RR, Visconti RP, Drake CJ. Recruitment of bone marrow-derived valve interstitial cells is a normal homeostatic process. J Mol Cell Cardiol 2011;51:955-965.
68. Trachtman H, Fervenza FC, Gipson DS, Heering P, Jayne DR, Peters H, et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-beta antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int 2011;79:1236-1243.
69. Chu Y, Lund DD, Weiss RM, Brooks RM, Doshi H, Hajj GP, et al. Pioglitazone attenuates valvular calcification induced by hypercholesterolemia. Arterioscler Thromb Vasc Biol 2013;33:523-532.
70. Li F, Cai Z, Chen F, Shi X, Zhang Q, Chen S, et al. Pioglitazone attenuates progression of aortic valve calcification via down-regulating receptor for advanced glycation end products. Basic Res Cardiol 2012;107:306.
71. Woldt E, Terrand J, Mlih M, Matz RL, Bruban V, Coudane F, et al. The nuclear hormone receptor PPARgamma counteracts vascular calcification by inhibiting Wnt5a signalling in vascular smooth muscle cells. Nat Commun 2012;3:1077.
72. Sun L, Chandra S, Sucosky P. Ex vivo evidence for the contribution of hemodynamic shear stress abnormalities to the early pathogenesis of calcific bicuspid aortic valve disease. PLoS One 2012;7:e48843.
73. Mori K, Jono S, Emoto M, Kawagishi T, Yasumoto H, Konishi T, et al. Effects of pravastatin on serum osteoprotegerin levels in patients with hypercholesterolemia and type 2 diabetes. Angiology 2010;61:86-91.
74. Phinikaridou A, Andia ME, Shah AM, Botnar RM. Advances in molecular imaging of atherosclerosis and myocardial infarction: Shedding new light on in vivo cardiovascular biology. Am J Physiol Heart Circ Physiol 2012;303:H1397-H1410.
75. Staub D, Partovi S, Imfeld S, Uthoff H, Baldi T, Aschwanden M, et al. Novel applications of contrast-enhanced ultrasound imaging in vascular medicine. Vasa 2013;42: 17-31.
76. Alfonso F, Sandoval J, Cardenas A, Medina M, Cuevas C, Gonzalo N. Optical coherence tomography: From research to clinical application. Minerva Med 2012;103: 441-464.
77. Becker W. Fluorescence lifetime imaging - techniques and applications. J Microsc 2012;247:119-136.
78. Werkmeister E, Kerdjoudj H, Marchal L, Stoltz JF, Dumas D. Multiphoton microscopy for blood vessel imaging: New non-invasive tools (Spectral, SHG, FLIM). Clin Hemorheol Microcirc 2007;37:77-88. (Pubitemid 47015814)
79. Ossege LM, Sindern E, Patzold T, Malin JP. Immunomodulatory effects of interferon-beta-1b in patients with multiple sclerosis. Int Immunopharmacol 2001;1: 1085-1100. (Pubitemid 32434426)
80. Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007;56:323-333. (Pubitemid 46106206)
81. Marshall JL WA, Rae J, DeLap RJ, Phipps K, Hanfelt J, Yunmbam MK, Sun JX DK, Hawkins MJ. Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer. Clin Cancer Res 1997;3(12 Pt 1): 2347-2354. (Pubitemid 28133154)
82. Ord JJ, Streeter E, Jones A, Le Monnier K, Cranston D, Crew J, et al. Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma. Br J Cancer 2005;92:2140-2147. (Pubitemid 40966248)
83. Lewis KD, Robinson WA, Millward MJ, Powell A, Price TJ, Thomson DB, et al. A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest New Drugs 2008;26:89-94.
84. Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 2011;96:972-980.
85. de Jonge MJ, Dumez H, Verweij J, Yarkoni S, Snyder D, Lacombe D, et al. Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours. Eur J Cancer 2006;42:1768- 1774. (Pubitemid 44149080)
86. Primrose JN, Bleiberg H, Daniel F, Van Belle S, Mansi JL, Seymour M, et al. Marimastat in recurrent colorectal cancer: Exploratory evaluation of biological activity by measurement of carcinoembryonic antigen. Br J Cancer 1999; 79:509-514. (Pubitemid 29046227)
87. Hirte H, Vergote IB, Jeffrey JR, Grimshaw RN, Coppieters S, Schwartz B, et al. A phase III randomized trial of BAY 12- 9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: A National Cancer Institute of Canada Clinical Trials Group Study. Gynecol Oncol 2006;102:300-308. (Pubitemid 44056259)
88. Beattie GJ, Smyth JF. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin Cancer Res 1998;4:1899-1902. (Pubitemid 28369173)
89. Saunders E, Ferdinand K, Yellen LG, Tonkon MJ, Krug- Gourley S, Poland M. Efficacy and safety of cerivastatin and pravastatin in the treatment of primary hypercholesterolemia. J Natl Med Assoc 2000;92:319-326.
90. Chiappori AA, Eckhardt SG, Bukowski R, Sullivan DM, Ikeda M, Yano Y, et al. A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clin Cancer Res 2007;13:2091-2099. (Pubitemid 46649877)
91. Paribello C, Tao L, Folino A, Berry-Kravis E, Tranfaglia M, Ethell IM, et al. Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol 2010;10:91.
92. Caton JG, Ciancio SG, Blieden TM, Bradshaw M, Crout RJ, Hefti AF, et al. Subantimicrobial dose doxycycline as an adjunct to scaling and root planing: Post-treatment effects. J Clin Periodontol 2001;28:782-789. (Pubitemid 33761320)
93. Rubin CJ, Viraswami-Appanna K, Fiedorek FT. Efficacy and safety of muraglitazar: A double-blind, 24-week, doseranging study in patients with type 2 diabetes. Diab Vasc Dis Res 2009;6:205-215.
94. Agarwal R, Saha C, Battiwala M, Vasavada N, Curley T, Chase SD, et al. A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. Kidney Int 2005;68:285-292. (Pubitemid 43181387)
95. Gerstein HC, Ratner RE, Cannon CP, Serruys PW, Garcia- Garcia HM, van Es GA, et al. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: The assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation 2010;121:1176-1187.
96. Goke B, Gause-Nilsson I, Persson A, Group GS. The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes. Diab Vasc Dis Res 2007;4:204-213. (Pubitemid 47529210)
97. Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011;365:327-336.
98. Henriksen K, Byrjalsen I, Qvist P, Beck-Nielsen H, Hansen G, Riis BJ, et al. Efficacy and safety of the PPARgamma partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy. Diabetes Metab Res Rev 2011;27:392-401.
99. Truitt KE GR, Rosenstock J, Chou HS, Merante D, Triscari J, Wang AC. A 26-week, placebo- and pioglitazone-controlled, dose-ranging study of rivoglitazone, a novel thiazolidinedione for the treatment of type 2 diabetes. Curr Med Res Opin 2010;26:1321-1331.
100. Salim K SU, Burstein S, Hoy L, Karst M. Pain measurements and side effect profile of the novel cannabinoid ajulemic acid. Neuropharmacology 2005;48:1164-1171. (Pubitemid 40725989)
101. Cohen SB PS, Kivitz AJ, Burch FX, Donohue JP, Burstein D, Sun YN, Banfield C VM, Ni L, Zack DJ. A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. Arthritis Res Ther 2011;13:R125.
102. Beeh KM BJ, Meyer M, Buhl R, Zahlten R, Wolff G. Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions ollowing allergen challenge in mild asthmatics: a randomized, double-blind, lacebo-controlled clinical cross-over-trial. Pulm Pharmacol Ther 2005;19:233-241.
103. Riechelmann H SA, Golze W, Hanft G, Schroen C, Hoermann K, Erhardt T, Gronau S. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol 2008;44:823-829.
104. Adler SG SS, Williams ME, Arauz-Pacheco C, Bolton WK, Lee T, Li D, Neff TB UP, Sewell KL. Phase 1 study of anti- CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin J Am Soc Nephrol 2010;5:1420-1428.
105. Lounkine E KM, Whitebread S, Mikhailov D, Hamon J, Jenkins JL, Lavan, P WE, Doak AK, Cô té S, Shoichet BK, Urban L. Large-scale prediction and testing of drug activity on side-effect targets. Nature 2012;486:361-367.
106. Costero O BM, del Peso G, Gil F, Aguilera A, Ros S, Hevia C, Selgas R. Treatment of anorexia and malnutrition in peritoneal dialysis patients with megestrol acetate. Adv Perit Dial 2004;20:209-212.
107. Mansel R GA, Nestour EL, Masini-Etévé V, O'Connell K. A phase II trial of Afimoxifene (4-hydroxytamoxifen gel) for cyclical mastalgia in premenopausal women. Breast Cancer Res Treat 2007;106:389-397. (Pubitemid 350029684)
108. deVoogt HJ P-MM, Sylvester R, Schröder FH. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer Trials 30761 and 30762. J Urol 1988;140:1557.
109. Wolff BG MF, Gerkin TM, Techner L, Gabriel K, Du W, Wallin BA. Alvimopan Postoperative Ileus Study Group. Alvimopan, a novel, peripherally acting mu opioid antagonist: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus. Ann Surg 2004;240:728-734.
110. Thü rlimann B WR, Senn HJ, Thiébaud D. Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: A prospective randomized crossover trial. Ann Oncol 1992; 3:619-623.
111. Li Q, Guo H, Chou DW, Harrington DJ, Schurgers LJ, Terry SF, et al. Warfarin accelerates ectopic mineralization in Abcc6 (- /-) mice: Clinical relevance to pseudoxanthoma elasticum. Am J Pathol 2013;182:1139-1150.
112. Leftheriotis G, Omarjee L, Le Saux O, Henrion D, Abraham P, Prunier F, et al. The vascular phenotype in pseudoxanthoma elasticum and related disorders: Contribution of a genetic disease to the understanding of vascular calcification. Front Genet 2013;4:4.
113. Gorgels TG, Teeling P, Meeldijk JD, Nillesen ST, van der Wal AC, van Kuppevelt TH, et al. Abcc6 deficiency in the mouse leads to calcification of collagen fibers in Bruch's membrane. Exp Eye Res 2012;104:59-64.
114. Helal I. Autosomal dominant polycystic kidney disease: New insights into treatment. Saudi J Kidney Dis Transpl 2013;24:230-234.
115. Komaba H, Fukagawa M. The role of FGF23 in CKD - with or without Klotho. Nat Rev Nephrol 2012;8:484-490.
116. Isakova T. Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease. Curr Opin Nephrol Hypertens 2012;21:334-340.
117. Molon B, Ugel S, Del Pozzo F, Soldani C, Zilio S, Avella D, et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med 2011;208: 1949-1962.
118. Hatch NE, Franceschi RT. FGF2 induced expression of the pyrophosphate generating enzyme, PC-1, is mediated by Runx2 and Msx2. J Musculoskelet Neuronal Interact 2008; 8:318-320.
119. Nagaraja S, Anslow P, Winter B. Craniosynostosis. Clin Radiol 2013;68:284-292.
120. Hatch NE. FGF signaling in craniofacial biological control and pathological craniofacial development. Crit Rev Eukaryot Gene Expr 2010;20:295-311.
121. Mackenzie NC, Zhu D, Milne EM, van 't Hof R, Martin A, Darryl Quarles L, et al. Altered bone development and an increase in FGF-23 expression in Enpp1 (- /-) mice. PLoS One 2012;7:e32177.